Journal article
Effect of APOE and a polygenic risk score on incident dementia and cognitive decline in a healthy older population
M Riaz, A Huq, J Ryan, SG Orchard, J Tiller, J Lockery, RL Woods, R Wolfe, AE Renton, AM Goate, R Sebra, E Schadt, A Brodtmann, RC Shah, E Storey, AM Murray, JJ McNeil, P Lacaze
Aging Cell | WILEY | Published : 2021
DOI: 10.1111/acel.13384
Abstract
Few studies have measured the effect of genetic factors on dementia and cognitive decline in healthy older individuals followed prospectively. We studied cumulative incidence of dementia and cognitive decline, stratified by APOE genotypes and polygenic risk score (PRS) tertiles, in 12,978 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial. At enrolment, participants had no history of diagnosed dementia, cardiovascular disease, physical disability or cognitive impairment. Dementia (adjudicated trial endpoint) and cognitive decline, defined as a >1.5 standard deviation decline in test score for either global cognition, episodic memory, language/executive function or p..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
The ASPREE Healthy Ageing Biobank was supported by a Flagship cluster (including the Commonwealth Scientific and Industrial Research Organisation, Monash University, Menzies Research Institute, Australian National University, University of Melbourne), Monash University and the National Cancer Institute at the National Institutes of Health (supplement to U01AG029824). The ASPREE clinical trial was supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (U01AG029824), the National Health and Medical Research Council (NHMRC) of Australia (334047 and 1127060), Monash University and the Victorian Cancer Agency. We thank the trial staff in Australia and the United States, the participants who volunteered for this trial, and the general practitioners and staff of the medical clinics who cared for the participants. We also thank the UK Biobank participants and admin staff. P. L is supported by a National Heart Foundation Future Leader Fellowship (102604).